Piper Sandler lowered the firm’s price target on Karyopharm (KPTI) to split-adjusted $15 from $75 and keeps an Overweight rating on the shares following transfer in analyst coverage. The firm says that the primary reason to own Karyopharm is for selinexor expansion into myelofibrosis and endometrial cancer. Karyopharm will report top-line Phase III SENTRY data on selinexor in combination with JAKIFY JAK-inhibitor naive myelofibrosis patients in the second half of 2025 and Phase III XPORT EC-042 data on selinexor maintenance therapy in TP53 wild-type endometrial cancer in mid-2026; both of which could expand the label and accelerate revenue growth in 2027, Piper adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm price target lowered to $54 from $75 at Baird
- Karyopharm target adjusted to $7 from $56 at H.C. Wainwright
- Karyopharm trading halted, news pending
- Karyopharm implementing 1-for-15 reverse stock split
- Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
Questions or Comments about the article? Write to editor@tipranks.com